Company news

Arvinas, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 22, 2025

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

April 20, 2025

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

April 3, 2025

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

March 26, 2025

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

March 10, 2025

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

February 10, 2025

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

February 2, 2025

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

January 9, 2025

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

December 9, 2024

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

November 26, 2024

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

November 24, 2024

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

October 29, 2024

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

October 21, 2024

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

October 20, 2024

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

July 29, 2024

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

June 23, 2024

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

June 20, 2024

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

June 16, 2024

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

May 22, 2024

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

May 15, 2024

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

May 8, 2024

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024

Arvinas to Present at Upcoming Investor Conferences

May 1, 2024

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

April 23, 2024

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

April 10, 2024

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

March 17, 2024

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 26, 2024

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

February 19, 2024

Arvinas Announces Chief Financial Officer Transition

February 19, 2024

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

February 5, 2024

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

January 31, 2024

Arvinas Appoints Jared Freedberg as General Counsel

January 15, 2024

Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program

December 4, 2023

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

December 4, 2023

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

November 27, 2023

Arvinas Announces Oversubscribed $350 Million Private Placement

November 26, 2023

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 6, 2023

Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

October 21, 2023

Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day

October 17, 2023

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

October 14, 2023

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

October 14, 2023

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 7, 2023

Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer

July 30, 2023

Arvinas Announces Changes to its Board of Directors

June 14, 2023

Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations

June 7, 2023

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

May 7, 2023

Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 4, 2023

Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference

May 2, 2023

Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial

May 1, 2023

Arvinas to Present at Stifel Targeted Oncology Day

April 20, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.